| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Amenamevir (JAN/INN); Amenalief (TN) | ||||||
| Formula | C24H26N4O5S | ||||||
| Exact mass | 482.1624 | ||||||
| Mol weight | 482.552 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate Metabolizing enzyme inducer DG02891 CYP2B6 inducer DG02853 CYP3A/CYP3A4 inducer | ||||||
| Remark |
| ||||||
| Efficacy | Antiviral, Helicase-primase inhibitor | ||||||
| Target | Herpesvirus helicase-primase complex [KO:K25235 K25236 K25237] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||
| Interaction | CYP induction: CYP3A [HSA:1576 1577 1551], CYP2B6 [HSA:1555] | ||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AX Other antivirals J05AX26 Amenamevir D10564 Amenamevir (JAN/INN) <JP> Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D10564 Amenamevir (JAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate D10564 Amenamevir Metabolizing enzyme inducer DG02891 CYP2B6 inducer D10564 Amenamevir DG02853 CYP3A/CYP3A4 inducer D10564 Amenamevir Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor Other inhibitor D10564 Amenamevir (JAN/INN) <JP> Antimicrobials abbreviations [BR:br08327] Antivirals Genome replication inhibitor Other inhibitor D10564 Amenamevir (JAN/INN) New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10564 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10564 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10564 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 34 1 C8x C 11.9700 -6.3700 2 C8y C 11.9700 -7.7700 3 C8x C 13.1824 -8.4700 4 C8x C 14.3949 -7.7700 5 C8y C 14.3949 -6.3700 6 C8x C 13.1824 -5.6700 7 C8y C 10.7576 -8.4700 8 N5x N 9.6185 -7.6884 9 O2x O 8.5269 -8.5318 10 C8x C 8.9916 -9.8306 11 N5x N 10.3705 -9.7900 12 N1b N 15.6260 -5.6590 13 C5a C 16.8312 -6.3547 14 C1b C 18.0135 -5.6719 15 N1c N 19.2075 -6.3612 16 O5a O 16.8316 -7.7696 17 C5a C 20.3954 -5.6752 18 C1y C 21.5865 -6.3629 19 O5a O 20.3955 -4.2702 20 C8y C 19.2077 -8.6797 21 C8y C 17.9747 -9.3921 22 C8x C 17.9751 -10.7921 23 C8x C 19.1878 -11.4918 24 C8x C 20.4208 -10.7793 25 C8y C 20.4204 -9.3793 26 C1x C 21.5866 -7.7697 27 C1x C 22.7991 -8.4697 28 S2x S 24.0115 -7.7696 29 C1x C 24.0114 -6.3627 30 C1x C 22.7989 -5.6628 31 O3c O 25.2239 -7.0696 32 O3c O 24.0115 -9.1696 33 C1a C 16.7684 -8.6961 34 C1a C 21.6469 -8.6705 BOND 37 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 2 7 1 8 7 8 2 9 8 9 1 10 9 10 1 11 10 11 2 12 7 11 1 13 5 12 1 14 12 13 1 15 13 14 1 16 14 15 1 17 13 16 2 18 15 17 1 19 17 18 1 20 17 19 2 21 15 20 1 22 20 21 2 23 21 22 1 24 22 23 2 25 23 24 1 26 24 25 2 27 20 25 1 28 18 26 1 29 26 27 1 30 27 28 1 31 28 29 1 32 29 30 1 33 18 30 1 34 28 31 2 35 28 32 2 36 21 33 1 37 25 34 1 |